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Background: Conditions associated with sudden cardiac arrest/death (SCA/D) in youth often have a genetic etiology.
While SCA/D is uncommon, a pro-active family screening approach may identify these inherited structural and electrical
abnormalities prior to symptomatic events and allow appropriate surveillance and treatment. This study investigated the
diagnostic utility of exome sequencing (ES) by evaluating the capture and coverage of genes related to SCA/D.
Methods: Samples from 102 individuals (13 with known molecular etiologies for SCA/D, 30 individuals without known
molecular etiologies for SCA/D and 59 with other conditions) were analyzed following exome capture and sequencing at
an average read depth of 100X. Reads were mapped to human genome GRCh37 using Novoalign, and post-processing
and analysis was done using Picard and GATK. A total of 103 genes (2,190 exons) related to SCA/D were used as a
primary filter. An additional 100 random variants within the targeted genes associated with SCA/D were also selected and
evaluated for depth of sequencing and coverage. Although the primary objective was to evaluate the adequacy of depth
of sequencing and coverage of targeted SCA/D genes and not for primary diagnosis, all patients who had SCA/D (known
or unknown molecular etiologies) were evaluated with the project’s variant analysis pipeline to determine if the molecular
etiologies could be successfully identified.
Results: The majority of exons (97.6 %) were captured and fully covered on average at minimum of 20x sequencing
depth. The proportion of unique genomic positions reported within poorly covered exons remained small (4 %). Exonic
regions with less coverage reflect the need to enrich these areas to improve coverage. Despite limitations in coverage,
we identified 100 % of cases with a prior known molecular etiology for SCA/D, and analysis of an additional 30 individuals
with SCA/D but no known molecular etiology revealed a diagnostic answer in 5/30 (17 %). We also demonstrated 95 %
of 100 randomly selected reported variants within our targeted genes would have been picked up on ES based on our
coverage analysis.
Conclusions: ES is a helpful clinical diagnostic tool for SCA/D given its potential to successfully identify a molecular
diagnosis, but clinicians should be aware of limitations of available platforms from technical and diagnostic perspectives.* Correspondence: lim@email.chop.edu
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The rapid development of genomic sequencing and tech-
niques such as massively parallel next-generation sequen-
cing has decreased cost, improved efficiency, and increased
the clinical and research use of genetic testing [1, 2]. Ex-
ome sequencing (ES), or sequencing the protein-coding
portions of a human genome, has become an increasingly
utilized approach for investigating Mendelian disorders [3].
Studies report varying diagnostic ES success rates, ranging
from 22.8 % [4] to 50 % [5]. As costs continue to decline, it
is likely the use of whole genome-sequencing will increase
[6]. The application of exome and genome-level sequen-
cing raises many challenges both from a technical execu-
tion and diagnostic standpoint [7, 8], and the best use of
this testing in clinical practice remains unclear [1]. The role
of genetic testing as a tool to investigate cardiovascular dis-
ease has had increased focus in recent years [9].
Sudden cardiac arrest/death (SCA/D) is uncommon
in the young and occurs in an estimated 2000 individ-
uals under 25 years of age annually in the US [10].
Causes include inherited structural, functional, and
electrical cardiac abnormalities [11–13]. There may be
no significant previous medical history prior to the oc-
currence of SCA/D, and standard postmortem analysis
may be unrevealing [12, 14, 15] in as many as 10-30 %
of cases [16]. A pro-active family screening approach is
important to provide life-saving treatment and to help
identify other affected members due to the high associ-
ation of genetic causes [12, 13]. More than 100 genes
have been associated with SCA/D [11, 17]. Guidelines for
genetic testing for channelopathies and cardiomyopa-
thies, were published in 2011 [18].
Increased accessibility to ES warrants its examination as
a possible front line diagnostic tool for inherited conditions
associated with SCA/D. Compared with targeted gene se-
quencing and comprehensive panels specific for disease,
which are currently available [11], there are important dif-
ferences to consider with ES. The workflow and challenges
of completing ES are described in detail by Bamshad et al.
[3]. Importantly, only 1-2 % of the human genome con-
tains protein–coding sequences [3, 6, 19]; thus, these re-
gions must undergo an exon-targeting “capture” process
before being sequenced. Traditional sequencing methods
for individual genes or panels do not require this step.
A second consideration is determining the “coverage”
of these captured regions. Coverage (also known as
“depth” of sequencing) refers to how many times a nu-
cleotide meeting criteria for being a high-quality base is
represented in a random collection of raw sequences
[20]. This helps differentiate sequencing errors from a
true sequence variant; the higher the coverage, the more
likely the captured base is accurate and not a false read
due to technical errors. For example, a captured base
“T” with 20x coverage means that base is represented atleast 20 times at that position in multiple raw sequences.
Of note, “coverage”, in addition to meaning depth of se-
quencing, may also refer to the general proportion of
bases covered in genomic sequence at a specific depth
[21]. For example, an exon with 90 % coverage at 20x
means 90 % of the bases in that exon are represented at
least 20 times on multiple raw sequences. In our manu-
script, depth of sequencing will refer to the number of
times a nucleotide is represented, and coverage will refer
to the general proportion of genomic sequence covered
unless otherwise specified.
Figure 1 outlines a basic schematic of a hypothetical
analysis of patients carrying pathogenic SCA/D variants
via ES and the steps that potentially can lead to missed
calls. Though there is much debate regarding the use and
implications of ES in a clinical setting, there is little infor-
mation available regarding the capture and coverage of
cardiac genes commonly found within comprehensive
panels, which has implications for diagnostics and ability
to find potential pathogenic mutations. The main object-
ive of this study was to investigate the utility of ES as a po-
tential diagnostic tool by investigating capture and depth
of coverage of a group of targeted genes related to SCA/D.
Methods
Study population
This research study was approved by The Children’s Hos-
pital of Philadelphia (CHOP) Institutional Review Board
(IRB). Samples from 102 pediatric individuals were en-
rolled under an IRB approved protocol of informed
consent at The Children’s Hospital of Philadelphia and de-
identified. Detailed demographic information of individ-
uals was not readily available due to the de-identification
process. Of these 102 patients, thirteen had known mo-
lecular diagnosis for SCA/D, 59 had known molecular eti-
ologies for other conditions including hearing loss,
intellectual disability and mitochondrial disease (all known
diagnoses were identified by Clinical Laboratory Improve-
ment Amendments certified laboratories), and 30 individ-
uals did not have known molecular etiologies for SCA/D.
Exome capture, sequencing, and bioinformatics
Peripheral blood from patients was collected in sterile
EDTA tubes (BD vacutainer) at Phlebotomy, Children’s
Hospital of Philadelphia. Blood tubes were stored immedi-
ately at 4 °C and Genomic DNA (gDNA) was manually
extracted using standard procedures with the Gentra
Puregene Blood Kit Plus (Qiagen, 158489). gDNA quality
was assessed on an agarose gel, Nanodrop spectropho-
tometer and quantified via the Qubit system. 3-6ug of
gDNA from each sample were prepared and sent to the
Beijing Genomics Institute (BGI) facility at CHOP. Exome
capture was done with Agilent SureSelect V4, and whole-
exome sequencing was completed on Illumina Hi-Seq
Fig. 1 General schematic of hypothetical analysis of patients carrying pathogenic SCA/D variants who undergo ES
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Sequencing reads were obtained in FASTQ format and
were examined via the Pediatric Genetic Sequencing Pro-
ject (PediSeq) exome sequence coverage analysis pipeline.
The sequence reads were mapped to human genome
assembly, GRCh37.p10, using Novoalign (V3.00.02)
(www.novocraft.com), which has been shown to optimize
alignment [22]. Coverage statistics per exons in the SCA/
D genes bed file were generated using GATK Depth of
Coverage tool version 2.2. Quality control steps to filter
out poorly mapped reads included minBaseQuality 20/
minMapping Quality 20 settings during variant calling
and removal of variants with a minimum depth of cover-
age of less than 20 reads. Multi-sample variant calling was
not done as patients are clinically evaluated and analyzed
independently. Refer to Additional file 1 for further details
regarding the sequencing protocol and data processing.
The primary aim of this study was to evaluate the ad-
equacy of depth of sequencing, coverage of targeted
SCA/D genes, and platform efficacy, not to identify indi-
vidual molecular diagnoses. Therefore, the main coverage
analysis was completed on the first 72 samples, regard-
less of their underlying clinical findings and molecular
etiologies. Of these 72 samples, additional analysis (de-
scribed at the end of the methods section) was com-
pleted on the 13 cases with known molecular causes for
SCA/D. In addition, diagnostic analysis was performed
on 30 patients without known causes for their SCA/D.
15 of these 30 patients (50 %) had variable prior genetic
workup that was non-diagnostic.
A list of 103 genes associated with SCA/D (Table 1) was
manually curated and used as a primary filter for analysis.
To determine the full scope of variants that could be
missed using ES, the first step was to determine the total
number of exons present within the targeted genes, and
within those exons, determine how many variants havebeen previously reported and suspected to be pathogenic.
Information regarding reported variants can be found in
the Human Gene Mutation Database (HGMD), a compre-
hensive database that aims to compile nuclear gene germ-
line mutations that have been associated with human
disease [23]. We recognize not all variants reported in
HGMD may be considered pathogenic, but for the pur-
poses of this study any variant reported in HGMD was
considered a potentially disease causing change that would
require further review if picked up on ES.
We then evaluated the proportion of different variant
types present within the 2,190 exons. This was critical as
changes such as large insertions or deletions do not have
specific genomic coordinates, and locating these changes
can be problematic due to current limitations of ES
technology. As large insertions and deletions were un-
likely to be picked up with ES without separate and add-
itional computational analyses, they were not included
in the final analysis.
The next round of analysis focused on three main as-
pects: 1) Examining how well the exons in the targeted
genes were captured on the Agilent SureSelect V4 plat-
form, 2) Of the exons that were captured, how adequate
was the depth of sequencing of these exons, using 20x
(when a nucleotide on average is represented at least 20
times in a group of random raw sequences) as our
standard for defining adequate depth of sequencing, and
3) Of the captured exons, what proportion of the exons
met criteria for adequate sequencing coverage (percent-
age of bases within the exons that are sequenced at an
appropriate read depth, which in this case was 20x).
Coverage scores of all 2,190 exons were obtained for
each sample individually, and then data for each exon
was averaged across all samples.
Although the primary objective of this study was to
evaluate the adequacy of depth of sequencing and
Table 1 Curated List of 103 Genes Associated with SCA/D
ABCC9 CAV3 ELN KCNE3 MYH6 RBM20 TCAP
ACTA2 CBS EMD KCNH2 MYH7 RYR2 TGFB3
ACTC1 COL3A1 EYA4 KCNJ2 MYL2 SCN1B TGFBR1
ACTN2 COL5A1 FBN1 KCNJ5 MYL3 SCN3B TGFBR2
AKAP9 COL5A2 FBN2 KCNJ8 MYLK2 SCN4B TMEM43
ANK2 CRYAB FHL2 KCNQ1 MYOZ2 SCN5A TMPO
ANKRD1 CSRP3 FKTN KRAS NEXN SDHA TNNC1
BAG3 CTF1 GATAD1 LAMA4 NRAS SGCD TNNI3
BRAF DES GLA LAMP2 PKP2 SHOC2 TNNT2
CACNA1B DMD GPD1L RPSA PLN SLC25A4 TPM1
CACNA1C DPP6 HRAS LDB3 PRKAG2 SLC2A10 TTN
CACNA2D1 DSC2 JPH2 LMNA PSEN1 SMAD3 TTR
CACNB2 DSG2 JUP MAP2K1 PSEN2 SNTA1 VCL
CALR3 DSP KCNE1 MYBPC3 PTPN11 SOS1
CASQ2 DTNA KCNE2 MYH11 RAF1 TAZ
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diagnosis, all patients enrolled in the study who had known
molecular etiologies for SCA/D were evaluated with the
project’s variant analysis pipeline to determine if the mo-
lecular etiologies could be successfully identified. Project
members completing this analysis were blinded to the
known molecular diagnosis of the patients to avoid bias
during the evaluation process. As this group of patients
was relatively small (n = 13), additional variants within the
targeted genes associated with SCA/D were selected and
evaluated for depth of sequencing and coverage to deter-
mine how well a random number of potentially disease re-
lated mutations would be picked up on ES. One hundred
variants reported in the Human Gene Mutation Database
(HGMD) that were within the 103 genes associated with
SCA/D were randomly selected for analysis to ensure a
varied distribution. Statistics regarding the capture and
depth of sequencing on those specific variants were gener-
ated using GATK Depth of Coverage tool version 2.2.
Beyond the 72 individuals used in the primary cover-
age analysis, the additional 30 patients with a history of
SCA/D but no known molecular causes were analyzed
using the same variant analysis pipeline to determine a
diagnostic yield. Results were deemed “positive” if there
were variants in genes related to SCA/D categorized as
likely pathogenic or pathogenic, “uncertain” if there were
only variants in genes related to SCA/D categorized as
variants of uncertain significance (VUS), and “negative”
if there were no VUS, suspected pathogenic, or patho-
genic variants identified in genes related to SCA/D.
Results
Within the 103 targeted genes associated with SCA/D,
there were 2,190 exons present (Fig. 2a). Within theseexons, the total number of reported variants suspected
to be disease causing in HGMD was 11,452 (Fig. 3). Of
the 11,452 variants reported in HGMD in our targeted
exons, 1,896 (16.6 %) were large deletions or insertions,
and 9,556 (83.4 %) were variants with a reported gen-
omic position (Fig. 3). Of these variants with a coordin-
ate, 8,578 (89.8 %) were associated with a unique
genomic position (e.g., base “T” at position “X”), and 978
(10.2 %) represented the number of positions with mul-
tiple base pair changes reported at the same position
(e.g., both base “T” and base “A” changes reported at
position “X”) (Fig. 3). Using our specific capture kit and
sequencing technology, 2,138 out of 2,190 exons were
captured (97.6 %), and 52 out of the 2,190 exons (2.4 %)
were not captured (Fig. 2a) during the sequencing
process. Within the captured exons, there were 8538
genomic positions (99.5 % of 8578 total genomic posi-
tions) published HGMD variants (Fig. 2b).
We were also interested in the proportion of unique
genomic positions falling within exons that were cap-
tured but had poor depth of sequencing and thus poten-
tially poor coverage. We considered an exon to have
inadequate coverage (“not covered” or “no coverage”)
when less than 40 % of the bases within the exon met
criteria for having sequence depth of at least 20x. Within
the 72 samples, the number of unique genomic positions
falling within captured exons that fell in this category
ranged from 44 to 587, with a median of 374. Averaged
across all 72 samples, there were approximately 344/
8538 (4 %) unique genomic positions falling within cap-
tured exons that had less than 40 % of bases sequenced
at 20x depth (“no coverage”).
In contrast, Fig. 4 delineates the proportion of exons
that met criteria for “adequate” sequencing coverage in
the captured exons. The exon proportions were sepa-
rated into different categories based on what percentage
of bases within the exons had adequate depth of sequen-
cing at 20x. We considered an exon “fully covered” if
100 % of the bases in that exon were covered at 20x,
“well covered” if ≥90 % to less than 100 % of bases in
the exon were covered at 20x, “mostly covered” if ≥70 %
to less than 90 % of the bases in the exon were covered
at 20x, lightly covered if ≥40 % to less than 70 % of the
bases in the exon were covered at 20x, and “not covered”
if <40 % of the bases in the exon were covered at 20x.
Proportions for each of the coverage categories were ob-
tained for samples individually, and then they were aver-
aged across all samples. On average, 81 % of the total
exons were fully covered, 5.04 % of exons were well cov-
ered, 4.91 % of exons were mostly covered, 3.39 % of
exons were lightly covered, and 5.66 % of exons were
not covered.
All patients enrolled in the study who had known mo-
lecular etiologies for SCA/D (n = 13) were also evaluated
Fig. 2 a, Distribution of captured versus non-captured exons within 103 targeted genes associated with SCA/D. b, Distribution of unique genomic
positions with reported pathogenic variants in Human Gene Mutation Database (HGMD) that fall within the captured and non-captured exons in
the targeted 103 genes associated with SCA/D. Genomic position (*) refers to the location of variant on a chromosome
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fied using the project’s variant analysis ES pipeline. Of
these patients, 13/13 pathogenic variants previously
called by CLIA certified laboratories were accurately
identified. Due to a small sample size, additional cover-
age analysis was performed on 100 random variants
within the 103 SCA/D genes reported in HGMD to
evaluate how well these would be picked up on ES (see
Additional file 2 for variant list). All 100 variants were
captured by the capture kit (Fig. 5). The next step was to
address adequate depth of sequencing. Using 20x as the
standard for defining adequate depth of sequencing, 95/
100 variants met this criteria, and the remaining 5/100Fig. 3 Distribution of reported Human Gene Mutation Database
(HGMD) variants within the exons of the 103 genes associated with
SCA/D list (n = 11,452)variants had a sequencing depth of less than 20x (Fig. 5;
Table 2). Of these variants, 3 had sequencing depths of
10x-19x, and 2 had a sequencing depth of less than 5x
(Fig. 5; Table 2).
An additional 30 patients with history of SCA/D and
no known molecular etiology were also analyzed using
the same variant analysis pipeline. Results revealed a
positive causative finding in 5/30 cases (17 %, Table 3),
uncertain results in 16/30 cases (53 %), and negative re-
sults in 9/30 (30 %).
Discussion
Our results revealed a number of findings demonstrating
the strengths and limitations of using ES as a diagnostic
tool. First, there was a fair percentage (16.6 %) of vari-
ants within the targeted genes reported in HGMD (large
deletions or insertions without genomic positions) that
would not be expected to be seen with ES due to the
limitations of current technology. Though the ability to
identify such changes will likely improve with better
technology, clinicians should be aware of the types of
platforms being used to capture exonic sequence as well
as the limitations of sequence and variant calling tech-
nologies to successfully sequence and identify certain
types of mutations. In our analysis, amongst the variants
reported that have a genomic position, the majority
(89.8 %) were unique genomic positions. We were pri-
marily interested in the number of unique genomic posi-
tions since presumably a position that has good depth of
Fig. 4 Average Percentage of Exon Coverage Categories of Targeted SCA/SCD Genes at 20x sequencing depth
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change at that location.
Second, the results demonstrate that the majority of
exons (97.6 %) within the targeted SCA/SCD genes were
captured with our specific capture kit. The remaining
small portion of exons (2.4 %) were not captured primarily
because our capture kit did not target these exons, so
these areas would not be expected to be picked up even
on subsequent sample runs. There are regions of DNA
that can be difficult to capture due to the inherent se-
quence/structure (e.g., repetitive and GC rich regions)
resulting in a technical inability to target and capture
every exon in the human genome. Thus, the proportion of
unique genomic positions reported in HGMD falling
within these non-captured regions would be potentiallyFig. 5 Schematic analysis of 100 random pathogenic variants, suspected p
in Human Gene Mutation Database (HGMD) in genes related to SCA/Dmissed. However, within the non-captured exons, there
were only 40 genomic positions (0.5 % of 8578 total gen-
omic positions) with published HGMD variants that
would not be expected to be picked up (Fig. 2b). This re-
flects the process was able to capture the majority of
exons with minimal reported HGMD positions missed
due to capture issues alone. It is important to be mindful
that the goal of individual capture kits is to obtain consist-
ent coverage on the desired targets, but capture and
coverage of the non-targeted regions will vary depending
on the run due to the limitations of technology.
Aside from the initial capture process, variants could
also be missed due to inadequate depth of sequencing. For
example, 2 out of 2,190 exons were targeted for capture
across all 72 samples but had zero depth of sequencingathogenic variants, or variants of uncertain significance (VUS) reported
Table 2 Randomly selected variants potentially associated with disease within targeted SCA/D genes with less than 20x sequencing
depth
Gene OMIMa # Phenotype Variant Sequencing depth
COL3A1 120180 Ehlers-Danlos syndrome IV c.3230G > T 12
CTF1 600435 Cardiomyopathy, dilated c.274G > A 2
PKP2 602861 Arrhythmogenic right ventricular dysplasia c.1237C > T 11
SDHA 600857 Complex II deficiency & Dilated cardiomyopathy, 1GG c.1664G > A 1
TMPO 188380 Cardiomyopathy, dilated c.2068C > T 13
aOnline Mendelian Inheritance in Man
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on sequences). Within captured exons of individual sam-
ples, we were most interested in the proportion of re-
ported HGMD unique genomic positions falling within
exons meeting criteria for “no coverage” because these
have the potential to be missed on ES analysis. There was
a wide range within individual samples, but overall the
average proportion of positions in non-covered regions
was relatively small (4 %). When examining the propor-
tion of the total number of exons that fell under different
coverage categories at 20x sequencing depth, there was a
wide distribution with the majority (81 %) of exons being
fully covered and a minority (5.66 %) of exons not covered
at all. The middle categories of well covered, mostly cov-
ered, and lightly covered (13.34 % of exon proportions in
aggregate) still made up a fair portion of exons without
complete coverage in our targeted gene list. Our results
highlight the variability that exists with coverage using ES,
and poorly covered regions, as well as moderately covered
regions would likely benefit from improving coverage en-
richment of kits in these areas. In spite of these limitations
in coverage, it is notable that all of the known pathogenic
mutations in the 13 samples with confirmed molecular
etiologies for SCA/D were identified by using ES (Table 4),
and causal findings were identified in 17 % of an add-
itional set of 30 SCA/D patients without known molecular
etiologies referred for primary analysis (Table 3). While
the main purpose of this study was not to identify diag-
nostic yields of a particular cohort, these results are re-
flective of how a primary diagnosis can successfully be
made using ES.
We took an additional step to evaluate 100 random vari-
ants that have been potentially associated with disease inTable 3 Pathogenic or likely pathogenic variants identified on ES in
Gene Phenotype of gene
SCN5A BrSa, DCMb, Familial atrial fib, Long QT
DSP ARVDc, DCM
KCNE1 Long QT
KCNH2 Long QT, Short QT
KCNQ1 Familial atrial fib, Long QT, Short QT
aBrugada syndrome, bDilated cardiomyopathy, cArrhythmogenic right ventricular dyour targeted SCA/D genes across all individual samples
(Additional file 2). The capture of these variants was ideal
with all 100 variants successfully captured by the capture
kit (Fig. 5). In terms of coverage, the majority (95/100) of
the variants were sequenced adequately at 20x and thus
would have been picked up on ES. Of the remaining vari-
ants with sequencing depths less than 20x, only 2 had se-
quencing depths less than 5x and would be likely to be
missed on ES (Fig. 5; Table 2). Although 20x is often the
ideal standard for sequencing depth, many analysis pipe-
lines include variants with lower cutoffs; thus, depending
on what analysis protocols are used, up to 5 % of these
particular variants may not have been picked up on ES
due to sequencing depth. In sum, although at this time ES
does not fully cover every base pair at 20x within our tar-
geted genes, the likelihood of a missed variant due to
coverage issues remains small.
Limitations
There are a number of limitations to this study that
should be considered. First, coverage data from this ana-
lysis was limited to the focused gene list that was cu-
rated by our team. It is recognized that all genes
associated with SDA/D are not included in this list and
that new genes are frequently discovered as updated in-
formation becomes available. Since the completion of
this study, we have added additional genes associated
with SCA/D to our list. A pathogenic variant may exist
in a patient, but it will not be picked up on ES if the
gene has not yet been associated with that particular
phenotype and/or human disease. Genes are uniquely
different in terms of genomic location, size, number of
exons, repeat regions and GC rich regions, and othersamples without prior known molecular diagnosis
Variant Protein change Zygosity
c.4867C > T p.Arg1623* Heterozygous
c.928dupG p.Glu310Glyfs*13 Heterozygous
c.226G > A p.Asp76Asn Heterozygous
c.1750G > A p.Gly584Ser Heterozygous
c.513C > A p.Tyr171* Heterozygous
splasia
Table 4 Pathogenic variants identified on ES in samples with known molecular diagnosis
# Gene Phenotype of gene Variant Protein change Zygosity Change found
1 KCNH2 Long QT, Short QT c.1882G > A p.Gly628Ser Heterozygous Yes
2 KCNQ1 Familial atrial fib, Long
QT, Short QT
c.1552 C > T p.Arg518a Heterozygous Yes
3 KCNH2 Long QT, Short QT c.1838C > T p.Thr613Met Heterozygous Yes
4 SCN5A BrSa, DCMb, Familial
atrial fib, Long QT
c.4978A > G p.Ile1660Val Heterozygous Yes
5 KCNQ1 Familial atrial fib, Long
QT, Short QT
c.704 T > A p.Ile235Asn Heterozygous Yes
6 MYL2 HCMc c.173G > A p.Arg58Gln Heterozygous Yes
7 KCNE1 Long QT c.226G > A p.Asp76Asn Heterozygous Yes
8 KCNQ1 Familial atrial fib, Long
QT, Short QT
c.1140G > T p.Arg380Ser Heterozygous Yes
9 MYH7 DCM, HCM, LVNCd c.2572C > T p.Arg858Cys Heterozygous Yes
10 MYL2 HCM c.173G > A p.Arg58Gln Heterozygous Yes





12 FBN1 Marfan syndrome c.2347 A > C Asn783His Heterozygous Yes
13 ACTC; TTN DCM, HCM, LVNC;
DCM, HCM
ACTC: c.806 T > C; TTN:
c.11323 G > A
Ile269Thr; Ala3775Thr Heterozygous Yes
aBrugada syndrome, bDilated cardiomyopathy, cHypertrophic cardiomyopathy, dLeft ventricular noncompaction
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capture exons and have appropriate coverage. As new
genes related to SCA/SCD are discovered, it is important
to consider how these might be best captured and what
is necessary to improve coverage. Sims et al. reviewed in
depth issues of sequencing coverage [21]. Definitions for
what constitutes specific coverage “levels” also vary
among institutions and should be taken into account
when performing ES analysis. Additionally, available ex-
ome capture kits differ between vendors, though func-
tionality has been found to be generally equal [3], and
reproducibility varies with each use, even when using
the same kits. Factors such as level of enrichment, gen-
omic library detail, and consistency of captured targets
play a role [3].
Finally, as the goal of ES is to identify those variants
that may be potentially pathogenic and disease causing,
it is equally important to have efficient strategies and ap-
propriate variant analysis pipelines. Without a solid ana-
lysis pipeline, consistent capture and high coverage
alone is not adequate to detect meaningful variants. A
pathogenic variant may be present, but if it is not tar-
geted in analysis it may not be found depending on the
filtering parameters. This consideration will continue to
be of importance even as the use of genome level se-
quencing potentially increases beyond ES in the future.
Genome sequencing would allow changes beyond the
coding regions to be identified, and it would not face the
technical challenges seen in ES such as exon captureand coverage. However, the number of potential variants
to analyze would increase tremendously and would be
require more sophisticated analysis pipelines to filter
and identify disease-causing changes.
Conclusions
Given the high genetic heterogeneity of conditions lead-
ing to SCA/SCD, genomic sequencing has the potential
to provide invaluable clinical information to high-risk
families and clinicians and to help identify at-risk indi-
viduals in whom management can help to prevent future
SCA/SCD. Our results revealed both the abilities and
limitations of using ES as a tool to evaluate genes related
to conditions associated with SCA/SCD. Although ES is
not fully comprehensive for our targeted genes at this
time compared to traditional single or multi-gene
panels, the majority of exons were still captured with
commercially available kits and were also fully covered
on average at 20x sequencing depth. Also, the propor-
tion of HGMD unique genomic positions reported
within poorly covered exons remained small. Exonic re-
gions with less coverage reflect the need to enrich these
regions to improve coverage. Despite limitations in
coverage, our results show ES has a strong potential to
pick up molecular changes as we were able to identify
100% of cases with known molecular etiologies for SCA/D
in our small cohort. Additionally, in a cohort of 30 patients
without a known molecular etiology for their SCA/D we
were able to identify a likely etiology in 17 %. We were also
Li et al. Human Genomics  (2015) 9:15 Page 9 of 9able to demonstrate at least 95 % of a number of randomly
selected HGMD reported variants would have been picked
up on ES as well based on coverage analysis. Overall, ES is
a helpful genetic diagnostic tool for SCA/SCD in the clin-
ical setting given its potential to successfully reveal a mo-
lecular diagnosis, but clinicians should be aware of
limitations of currently available platforms from both a
technical and diagnostic perspective.
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